METTLER TOLEDO INTERNATIONAL INC/

Mettler-Toledo International Inc. is a leading global supplier of precision instruments and services, holding global number-one market positions in most of its businesses. The company's solutions are critical in research and development, quality control, and manufacturing processes for customers in a wide range of industries including life sciences, food, and chemicals. Its products are sold in more than 140 countries with a direct presence in approximately 40 countries. The business is geographically diversified, with net sales in 2025 derived 42% from North and South America, 29% from Europe, and 29% from Asia and other countries.

The company holds strong leadership positions in all of its businesses and believes it holds global number-one market positions in most of them. Primary competitors are numerous regional or specialized competitors, many of which are well established in their markets, including divisions of larger companies with potentially greater financial and other resources. Competitive advantages include worldwide market leadership positions, global brand and reputation, a track record of technological innovation, a comprehensive high-quality solution offering, a global sales and service offering, a large installed base of instruments, and diversification of the revenue base by geographic region, product range, application, and customer. The company estimates it has the largest installed base of weighing instruments in the world.

The company generates revenue through the manufacture and sale of precision instruments and the provision of value-added services. Net sales comprise product sales of precision instruments and related services. Service revenues are primarily derived from repair and other services, including regulatory compliance qualification, calibration, certification, preventative maintenance, and spare parts. Service accounted for approximately 25% of net sales in 2025 ¹, 24% in 2024 ², and 23% in 2023 ³. The customer base is diversified by industry and by individual end-customer, with no single end-customer accounting for more than 1% of 2025 net sales ⁴. Products are sold through a variety of distribution channels, with sales through direct channels exceeding sales through indirect channels.

The company's principal products and services are organized into three categories: laboratory, industrial, and retail. The laboratory instruments and related service business accounted for approximately 56% of net sales in 2025 ⁵ and 2024 ⁶, compared to 55% in 2023 ⁷. Laboratory instruments include balances, liquid pipetting solutions, automated lab reactors, titrators, pH meters, process analytics sensors, physical value analyzers, thermal analysis systems, UV/VIS spectrophotometers, moisture analyzers, cell counters, and the LabX software platform. The industrial instruments and related service business accounted for approximately 39% of net sales in 2025 ⁸, 2024 ⁹, and 2023 ¹⁰. Industrial products include industrial scales, terminals, transportation and logistics solutions, vehicle scale systems, industrial software, and product inspection systems such as metal detectors, x-ray systems, checkweighers, and camera-based imaging equipment. The retail business accounted for approximately 5% of net sales in 2025 ¹¹ and 2024 ¹², compared to 6% in 2023 ¹³. Retail offerings include weighing and software solutions for supermarkets and food retail businesses, including automated packaging and labeling solutions.

In 2025, the company acquired several North American distributors that increased direct market access while expanding the service business, as well as an extension of its life science equipment offering and other acquisitions. The cumulative initial cash payments were $93.8 million ¹⁴ and the company may be required to pay additional consideration of up to $35.5 million ¹⁵. Goodwill recorded in connection with the acquisitions totaled $56.0 million ¹⁶. The company also recorded $38.9 million ¹⁷ of identified intangibles primarily pertaining to customer relationships, which will be amortized on a straight-line basis over 5 to 10 years ¹⁸. In November 2025, the Board of Directors authorized an additional $2.75 billion ¹⁹ to the share repurchase program, which had $3.7 billion ²⁰ of remaining availability as of December 31, 2025. During 2025, the company spent $800 million ²¹ on the repurchase of 646,608 shares ²² at an average price per share of $1,237.18 ²³. In January 2025, the company entered into an agreement to issue and sell EUR 100 million ²⁴ 10 1/2-year Senior Notes with a fixed interest rate of 3.80% ²⁵ in a private placement, which will mature in July 2035.

Net sales in U.S. dollars increased 4% in 2025 ²⁶ and 2% in 2024 ²⁷. Excluding the effect of currency exchange rate fluctuations, net sales increased 3% in both 2025 ²⁸ and 2024 ²⁹. Net sales were $4.0 billion ³⁰ for the year ended December 31, 2025, compared to $3.9 billion ³¹ in 2024 and $3.8 billion ³² in 2023. Gross profit as a percentage of net sales was 59.4% for 2025 ³³, 60.1% for 2024 ³⁴, and 59.2% for 2023 ³⁵. Net earnings were $869.193 million ³⁶ in 2025, compared to $863.140 million ³⁷ in 2024 and $788.778 million ³⁸ in 2023. Diluted earnings per common share were $42.05 ³⁹ in 2025, compared to $40.48 ⁴⁰ in 2024 and $35.90 ⁴¹ in 2023. Cash provided by operating activities totaled $955.8 million ⁴² in 2025, compared to $968.3 million ⁴³ in 2024 and $965.9 million ⁴⁴ in 2023.

The company expects to continue to benefit from market trends toward automation and digitalization in 2026. It also anticipates future opportunities with customer replacement cycles and investments in on/near-shoring activities. However, timing remains unclear and many end-markets, including pharma/biopharmaceutical, food, and chemical, remain challenged and continue to face uncertainty. The company believes it will benefit from favorable pharma/biopharma market trends in the future and from increased customer demand for automation, digitalization, and safety; new facility investments; and continued focus on regulatory compliance including data integrity requirements. In 2026, the company will continue to pursue overall business growth strategies including gaining market share, focusing on faster-growing markets, extending its technology lead, expanding margins, and pursuing strategic acquisitions.

The company's growth strategy includes gaining market share through its global sales and marketing initiative, Spinnaker, which uses digitalization and advanced data analytics to identify, prioritize, and pursue growth opportunities. Emerging markets, comprising Asia (excluding Japan), Eastern Europe, Latin America, the Middle East, and Africa, account for approximately 33% of total net sales ⁴⁵, of which 16% relates to China ⁴⁶. The company has a two-pronged strategy in emerging markets: to capitalize on long-term growth opportunities and to leverage low-cost manufacturing operations in China, which was recently designated a Lighthouse site by the World Economic Forum's Global Lighthouse Network. The company has a nearly 40-year track record in China, and sales in Asia have grown more than 10% on a compound annual growth basis in local currencies since 2000 ⁴⁷. Overall, versus the prior year, the company experienced a 3% increase in emerging market local currency sales by destination during 2025 ⁴⁸, which included a local currency sales increase of 1% in China ⁴⁹ and 5% in other emerging markets ⁵⁰. The company also pursues other faster-growth vertical markets including semiconductors, advanced materials, and new energy.

The company continues to strive to improve its margins by enhancing its value proposition via innovation, more effectively pricing products and services, optimizing its cost structure, and improving its mix in higher-margin businesses such as service. The company has implemented productivity and cost savings initiatives over recent years to mitigate reduced volume, while also focusing on reallocating resources to better align its cost structure to support investments in market penetration initiatives, higher-growth/profitable areas, and opportunities for margin improvement. The company has also implemented global procurement and supply chain management programs over the last several years aimed at lowering costs and has increased its focus on these programs with its SternDrive initiative, a global operational excellence program for continuous improvement efforts within supply chain, manufacturing, and back-office operations. Blue Ocean is also an important enabler of various margin expansion initiatives.

Capital expenditures in 2026 are expected to approximate $130 million ⁵¹, subject to business and economic conditions and foreign currency fluctuations. The company continues to explore potential acquisitions. In 2026, the company intends to spend in the range of $825 million to $875 million ⁵² on the repurchase of shares, subject to business and economic conditions. The company's share repurchase program does not obligate it to acquire any specific number of shares. The company expects to make interest payments of approximately $71.0 million ⁵³ during 2026 associated with its debt outstanding as of December 31, 2025.

The company faces a difficult environment due to global trade disputes/tariffs, governmental policies, and geopolitics that increased uncertainty in end markets and the global economy, while having a negative impact on customer behavior and import costs. The company estimates it incurred costs before mitigation actions from the 2025 incremental tariffs of approximately $50 million ⁵⁴ in 2025. Incremental tariff rates are currently 15% on imports from Switzerland ⁵⁵, 25% on non-USMCA imports from Mexico ⁵⁶, 30% on imports from China ⁵⁷, 15% on imports from the European Union ⁵⁸, and 10% on imports from the United Kingdom ⁵⁹. The U.S. government has indicated it may make further changes to tariff rates in the future that may adversely impact financial results in future periods. The recent escalation in global trade disputes/tariffs has increased economic uncertainty in end markets and the global economic environment, including increasing the risk of recession in many countries, and market conditions may change quickly.

Many of the company's end-markets, including pharma/biopharmaceutical, food, and chemical, remain challenged and continue to face uncertainty. The company recently experienced reduced demand in these segments, which negatively impacted net sales over the past few years. Market demand in pharma/biopharmaceutical was particularly impacted in 2023 after significant growth during the COVID-19 pandemic. The company's laboratory sales grew modestly in 2025 including improved bioprocessing market conditions, while biotech research and academia market conditions were softer. China and emerging market economies have historically been an important source of growth, but China has historically been volatile, and market conditions may change unfavorably due to various factors. The company's core industrial-related products are especially sensitive to changes in economic growth.

The company faces significant risks from its international operations, particularly its concentration in China, which accounted for 16% of sales to external customers ⁶⁰, 29% of total segment profit ⁶¹, and approximately 29% of global production ⁶² during 2025. Market demand in China declined significantly during the second half of 2023, which continued in 2024 ⁶³. The company is also subject to risks from tariffs and trade restrictions, estimating it incurred costs of approximately $50 million ⁶⁴ from 2025 incremental tariffs. Currency fluctuations pose a material risk, with a 1% strengthening of the Swiss franc against the euro estimated to reduce earnings before tax by approximately $2.8 million to $3.1 million annually ⁶⁵, and a 1% weakening of the Chinese renminbi against the U.S. dollar estimated to reduce earnings before tax by approximately $2.2 million to $2.6 million annually ⁶⁶. A prolonged downturn or additional consolidation in the pharma/biopharmaceutical, food manufacturing, and chemical industries could adversely affect operating results, as the company recently experienced reduced demand in these segments ⁶⁷. The company's debt level of approximately $2.2 billion ⁶⁸ as of December 31, 2025, net of cash of $66.9 million ⁶⁹, could make it more difficult to satisfy obligations and limit the ability to respond to business opportunities.

Management's message emphasizes the company's resilience and agility in a difficult environment due to global trade disputes/tariffs, governmental policies, and geopolitics. Management highlights that the team's resilience and agility, and the company's pricing, supply chain, productivity, and cost savings initiatives, were critical to mitigating these challenges. The company continues to benefit from strong global leadership positions, a diversified customer base, innovative product offering, investment in emerging markets, a significant installed base, and the impact of sophisticated global sales and marketing programs. Management states that the company is well positioned and has continued to make investments to further strengthen its portfolio and capture future growth opportunities. As the company enters 2026, it expects to continue to benefit from market trends toward automation and digitalization and anticipates future opportunities with customer replacement cycles and investments in on/near-shoring activities. Management also notes that the company has implemented various actions to fully offset the effect of the current incremental tariffs in 2026 ⁷⁰.